Jolanta Kunikowska

Prof. Dr. Jolanta Kunikowska

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MBMurat Fani BOZKURT
Murat Fani BOZKURT
IVIrene Virgolini
Irene Virgolini
Soňa BalogováSoňa Balogová
Soňa Balogová
MBMohsen Beheshti
Mohsen Beheshti
DRDomenico Rubello
Domenico Rubello
Stefano FantiStefano Fanti
Stefano Fanti

2 October 2013 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile
NANaomi Alazraki
Naomi Alazraki
JAJohn N. Aarsvold
John N. Aarsvold
RARiccardo A. Audisio
Riccardo A. Audisio
EGEdwin Glass
Edwin Glass
SVSergi Vidal-Sicart
Sergi Vidal-Sicart

7 May 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
JKJolanta Kunikowska
Jolanta Kunikowska
LKLeszek Królicki
Leszek Królicki
AHAlicja Hubalewska-Dydejczyk
Alicja Hubalewska-Dydejczyk
RMRenata Mikołajczak
Renata Mikołajczak
ASAnna Sowa-Staszczak
Anna Sowa-Staszczak
DPDariusz Pawlak
Dariusz Pawlak
Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy 90Y beta emitter for larger lesions and the lower energy 177Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined 90Y/177Lu-DOTATATE therapy in comparison to 90Y-DOTATATE alone. Methods Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n = 25) was treated with 90Y-DOTATATE, whereas group B (n = 25) received the 1:1 90Y/177Lu-DOTATATE. The administered activity was based on 3.7 GBq/m2 body surface area in three to five cycles, with amino acid infusion for nephroprotection. Results The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p = 0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p > 0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. Conclusion The results indicate that therapy with tandem radioisotopes (90Y/177Lu-DOTATATE) provides longer overall survival than with a single radioisotope (90Y-DOTATATE) and the safety of both methods is comparable.

29 November 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LKLeszek Królicki
Leszek Królicki
FBFrank Bruchertseifer
Frank Bruchertseifer
JKJolanta Kunikowska
Jolanta Kunikowska
HKHenryk Koziara
Henryk Koziara
BKBartosz Królicki
Bartosz Królicki
AMAlfred Morgenstern
Alfred Morgenstern

30 April 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
LKLeszek Królicki
Leszek Królicki
FBFrank Bruchertseifer
Frank Bruchertseifer
JKJolanta Kunikowska
Jolanta Kunikowska
HKHenryk Koziara
Henryk Koziara
BKBartosz Królicki
Bartosz Królicki
AMAlfred Morgenstern
Alfred Morgenstern
Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha emitters, e.g. 213Bi, that deposit their high energy within a short range allow the selective irradiation of tumor cells while sparing adjacent neuronal structures.

13 September 2024 in Science Advances
Verified
Journal Article
Open access
PMPawel Moskal
Pawel Moskal
JBJakub Baran
Jakub Baran
SBSteven Bass
Steven Bass
JCJarosław Choiński
Jarosław Choiński
NCNeha Chug
Neha Chug
Ewa Łucja StępieńEwa Łucja Stępień
Ewa Łucja Stępień
Positronium is abundantly produced within the molecular voids of a patient’s body during positron emission tomography (PET). Its properties dynamically respond to the submolecular architecture of the tissue and the partial pressure of oxygen. Current PET systems record only two annihilation photons and cannot provide information about the positronium lifetime. This study presents the in vivo images of positronium lifetime in a human, for a patient with a glioblastoma brain tumor, by using the dedicated Jagiellonian PET system enabling simultaneous detection of annihilation photons and prompt gamma emitted by a radionuclide. The prompt gamma provides information on the time of positronium formation. The photons from positronium annihilation are used to reconstruct the place and time of its decay. In the presented case study, the determined positron and positronium lifetimes in glioblastoma cells are shorter than those in salivary glands and those in healthy brain tissues, indicating that positronium imaging could be used to diagnose disease in vivo.